Skip to content

Effect of Traditional Chinese Medicine on In Vitro Fertilization (IVF) Success Rates

A Randomized, Controlled Clinical Trial of the Effect of Traditional Chinese Medicine on IVF Success Rates

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01331395
Acronym
TCM-P002
Enrollment
8
Registered
2011-04-08
Start date
2011-06-30
Completion date
2013-06-30
Last updated
2015-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Female Infertility, Secondary Female Infertility

Keywords

Infertility, IVF, Acupuncture

Brief summary

The purpose of this study is to determine the value of combining Traditional Chinese Medicine (TCM) Protocols including acupuncture with In Vitro Fertilization (IVF).

Interventions

OTHERTraditional Chinese Medicine

Active arm will receive Acupuncture with their IVF cycle.

Sponsors

Pacific Fertility Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 42 Years
Healthy volunteers
Yes

Inclusion criteria

1. Subject is able to understand and provide consent 2. Subject is female, 21-42 years of age at time of screening and has at least one l ovary 3. Subject BMI is \> 18 and \< 32 4. Subject is experiencing primary or secondary infertility 5. Subject may receive sperm from donated source 6. Subject's partner has sperm in the ejaculate 7. Subject's serum basal FSH is \< 11 IU/L 8. Subject's serum basal estradiol level is between 20-80 pg/mL 9. Subject's TSH level is \< 3.0 mv/mL 10. Subject's prolactin level is \< 24 ng/mL 11. Subject will agree to limit caffeine intake to one cup (76.5 mL/day) by the time of randomization 12. Subject agrees not to make alterations in diet and lifestyle practices other than those that their Medical Practitioner deems necessary in the best interest of the subject 13. Subject agrees not to participate in any other research opportunities for the duration of the study

Exclusion criteria

1. Subject is pursuing sex selection 2. Subject is undergoing treatment with an egg donor 3. Subject experienced more than 2 previous failed cycles 4. Subject is undergoing a heparin or lovenox-based protocol 5. Subject is currently taking herbal therapy (1 week wash-out) 6. Subject is currently taking co-interventions of moxibustion and cupping 7. Subject is exhibiting uterine anomalies (i.e.,bicornuate, unicornuate uterus,) 8. Subject is diagnosed with severe endometriosis defined as endometriomas \> 4cm 9. Subject is currently receiving acupuncture therapy (Subject must agree to a 30 day washout period prior to randomization) 10. Subject has history of recurrent spontaneous abortions defined as \> 3 11. Subjects with a Beck Depression Inventory (BDI-II) of 29 or higher at screening, indicative of severe depression, will be excluded from the study and referred for further psychological evaluation by our in-house licensed mental health professional.

Design outcomes

Primary

MeasureTime frameDescription
The proportion of subjects who receive an embryo transfer which results in a live birth.Average of 1 yearEmbryo transfer resulting in Live Birth up to 40 weeks gestation
The proportion of subjects in the active treatment group experiencing no SAE's attributable to ACU.Overall to be collected at interim analysis of 138 subjects and at study completion of 276 patients

Secondary

MeasureTime frameDescription
1. The proportion of subjects who undergo an embryo transfer which results in implantation as evidenced by USS at 7 weeks.Average of 4 monthsAt 7 week ultrasound
Effect of the IVF/ICSI treatment on quality of life and psychological factors assessed with the Fertility Quality of Life Questionnaire (FertiQoL 2008) and the Spielberger State Trait Anxiety Inventory (STAI).Average of two monthsRepeat measures at Screening, Treatment Month and at Embryo Transfer

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026